Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margherita Torti

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
International Review of Neurobiology|August 15, 2017
Constipation in Parkinson's DiseaseFabrizio Stocchi, Margherita Torti
Drug Design, Development and Therapy|February 27, 2016
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamideFabrizio Stocchi, Margherita Torti
Expert Opinion on Pharmacotherapy|September 21, 2018
Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?Margherita Torti, Laura Vacca, Fabrizio Stocchi
Expert Opinion on Pharmacotherapy|August 26, 2016
Advances in dopamine receptor agonists for the treatment of Parkinson's diseaseFabrizio Stocchi, Margherita Torti, Chiara Fossati
Expert Opinion on Pharmacotherapy|September 15, 2015
Rasagiline for the treatment of Parkinson's disease: an updateFabrizio Stocchi, Chiara Fossati, Margherita Torti
Expert Opinion on Drug Safety|September 2, 2020
Safety considerations when using non-ergot dopamine agonists to treat Parkinson's diseaseFabrizio Stocchi, Barbara Fossati, Margherita Torti
Expert Opinion on Drug Safety|February 5, 2014
Drug safety evaluation of ropinirole prolonged releaseFabrizio Stocchi, Fabiana G Radicati, Margherita Torti
Expert Opinion on Drug Metabolism & Toxicology|November 28, 2018
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's diseaseFabrizio Stocchi, Laura Vacca, Paola Stirpe, et al.
Expert Opinion on Pharmacotherapy|February 25, 2021
An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's diseaseFabrizio Stocchi, Laura Vacca, Andrea Grassi, et al.
Drugs|April 11, 2019
Are All Dopamine Agonists Essentially the Same?Margherita Torti, Daniele Bravi, Laura Vacca, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
International Review of Neurobiology|August 15, 2017
Constipation in Parkinson's DiseaseFabrizio Stocchi, Margherita Torti
Drug Design, Development and Therapy|February 27, 2016
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamideFabrizio Stocchi, Margherita Torti
Expert Opinion on Pharmacotherapy|September 21, 2018
Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?Margherita Torti, Laura Vacca, Fabrizio Stocchi
Expert Opinion on Pharmacotherapy|August 26, 2016
Advances in dopamine receptor agonists for the treatment of Parkinson's diseaseFabrizio Stocchi, Margherita Torti, Chiara Fossati
Expert Opinion on Pharmacotherapy|September 15, 2015
Rasagiline for the treatment of Parkinson's disease: an updateFabrizio Stocchi, Chiara Fossati, Margherita Torti
Expert Opinion on Drug Safety|September 2, 2020
Safety considerations when using non-ergot dopamine agonists to treat Parkinson's diseaseFabrizio Stocchi, Barbara Fossati, Margherita Torti
Expert Opinion on Drug Safety|February 5, 2014
Drug safety evaluation of ropinirole prolonged releaseFabrizio Stocchi, Fabiana G Radicati, Margherita Torti
Expert Opinion on Drug Metabolism & Toxicology|November 28, 2018
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's diseaseFabrizio Stocchi, Laura Vacca, Paola Stirpe, et al.
Expert Opinion on Pharmacotherapy|February 25, 2021
An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's diseaseFabrizio Stocchi, Laura Vacca, Andrea Grassi, et al.
Drugs|April 11, 2019
Are All Dopamine Agonists Essentially the Same?Margherita Torti, Daniele Bravi, Laura Vacca, et al.
Pageof 3